The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 10)
Rapid Response Innovation Awards, 2014
Pramipexole (Mirapex) is a drug that is effective at alleviating movement deficits associated with Parkinson's disease. However, pramipexole can induce compulsive behaviors and behavioral addictions, such as problem gambling, in some patients. Mirtazapine, an atypical antidepressant reduces the effects of drug addiction in pre-clinical models and in humans. This st...
Research Grant, 2013
The mu opioid receptor (MOR) has long been proposed as an appealing target for managing levodopa-induced dyskinesia and therefore received attention from industry, which developed a series of MOR antagonists (to block its activity). As some of those antagonists were active and some were not, further characterization was undertaken in in vitro experiments. In an experiment on MO...
Researchers: Erwan Bezard, PhD
Dyskinesia Challenge, 2012
Levodopa is the mainstay of treatment for the motor symptoms of Parkinson's disease. Unfortunately one of the long term side effects of levodopa treatment is the development of disabling involuntary movements known as LIDs. LIDs present serious challenges to the control of PD symptoms and the quality of life of PD patients. While there are currently no drugs approved for t...
Researchers: Ian Irwin, PhD
MJFF Research Grant, 2011
Mutations in the protein leucine-rich repeat kinase 2 (LRRK2) are the most common cause of inherited Parkinson's disease (PD). Interestingly, the penetrance LRRK2 mutations and the associated pathology are variable. Thus, there remains much to be learned on the role of LRRK2 mutations in PD. The main goals of this work are to characterize the behavioral, neurochemical, and p...
Researchers: J. Timothy Greenamyre, MD, PhD
Rapid Response Innovation Awards, 2011
All persons experience psychological stress. In fact, its pervasiveness is the primary cause of countless diseases. Although the impact of psychological stress on Parkinson's disease (PD) has yet to be fully defined, there is ample evidence that PD symptoms worsen during times of stress. Therefore, we asked what would happen if a pre-clinical model with a known genetic vulner...